Product
TACE plus Camrelizumab + Apatinib
1 clinical trial
4 indications
Indication
Hepatocellular CarcinomaIndication
Transarterial ChemoembolizationIndication
CamrelizumabIndication
ApatinibClinical trial
Transarterial Chemoembolization Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma : a Randomised , Open Label, Multicenter Controlled TrialStatus: Recruiting, Estimated PCD: 2026-06-30